Liwanli Innovation CoTPE:3054 -6.10%57 EBITDA Margin % is 446.56% as of Dec. 2025, which is 1934% above its 10-year median of 21.96. GuruFocus rates TPE:3054 with a GF Score™ of 57/100 and a GF Value™ of NT$39.71 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 955 Drug Manufacturers companies, Liwanli Innovation Co ranks better than 98.85% on this metric.
Liwanli Innovation Co (TPE:3054) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Liwanli Innovation Co EBITDA Margin % Related Terms
Liwanli Innovation Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Liwanli Innovation Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Liwanli Innovation Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liwanli Innovation Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liwanli Innovation Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Liwanli Innovation Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liwanli Innovation Co (TPE:3054) has a EBITDA Margin % of 446.56% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Liwanli Innovation Co and its competitors. This is 1934% above median its historical median of 21.96. According to the industry distribution chart, Liwanli Innovation Co ranks #11 out of 955 companies in the Drug Manufacturers industry, placing it in the top 1.2%.
Is Liwanli Innovation Co's EBITDA Margin % too high?
Liwanli Innovation Co's current EBITDA Margin % of 446.56% is 1934% above median its 10-year median of 21.96. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Liwanli Innovation Co's value of 446.56% is 3489.7% above this industry median. Based on the distribution chart, Liwanli Innovation Co ranks #11 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Liwanli Innovation Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Liwanli Innovation Co's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Liwanli Innovation Co ranks #11 out of 955 companies for EBITDA Margin %. This places Liwanli Innovation Co in the top 1% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.44. Liwanli Innovation Co's value of 446.56% is 3489.7% above this benchmark. While the company's 10-year median is 21.96 vs. the industry median of 12.44, Liwanli Innovation Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liwanli Innovation Co's current EBITDA Margin % of 446.56% is 3489.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Liwanli Innovation Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liwanli Innovation Co's current EBITDA Margin % is 446.56%, which is 1934% above median its own 10-year median of 21.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liwanli Innovation Co stock overvalued right now?
Based on GuruFocus' analysis, Liwanli Innovation Co (TPE:3054) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$39.71, compared to a current price of NT$61.60 — trading 55.1% above its estimated fair value. The current EBITDA Margin % is 446.56%, which is 1934% above median its 10-year median of 21.96 and 3489.7% above the Drug Manufacturers industry median of 12.44. Liwanli Innovation Co's overall GF Score™ is 57/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Liwanli Innovation Co (TPE:3054), the current EBITDA Margin % is 446.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liwanli Innovation Co (TPE:3054) Overvalued in 2026?
Based on GuruFocus' analysis, Liwanli Innovation Co stock appears to be overvalued.
The current stock price of NT$61.60 is trading 55.1% above its estimated GF Value™ of NT$39.71.
GuruFocus considers Liwanli Innovation Co to be Significantly Overvalued.
Key valuation signals for TPE:3054:
EBITDA Margin %: 446.56% (1934% above median its 10-year median of 21.96)
GF Value™: NT$39.71 vs. price of NT$61.60 (55.1% above fair value)
Industry Position: 3489.7% above the Drug Manufacturers median (#11 of 955)
No single metric tells the full story. See the TPE:3054 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liwanli Innovation Co Ltd is engaged in the manufacture, wholesale, and retail of electronic materials and the sales of biotech products like drug nutrient products. The reportable segments of the company are distinguished by products; the electronic department is mainly engaged in the sale and after-sales service of computer peripherals, memory and other related products; and the biotechnology department is mainly engaged in the sales of biotechnology products. Maximum revenue is generated from its Electronics department. Geographically, it generates a majority of its revenue from Taiwan, followed by other regions.
57GF Score
Get the complete analysis for TPE:3054
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:3054 has been successfully added to your 
